PolyMedix Presents Data On Anti-Tuberculosis Activity Of Its Novel Antibiotic Compounds

Main Category: Tuberculosis
Also Included In: Respiratory / Asthma;  Infectious Diseases / Bacteria / Viruses
Article Date: 30 Sep 2008 - 2:00 PDT

email to a friend   printer friendly   opinions  

PolyMedix, Inc. an emerging biotechnology company developing acute care products for infectious diseases and acute cardiovascular disorders based on biomimetics, presented new data at the "New Directions in AIDS Treatment Research Policy and Care Symposium" in New York on September 26th, 2008. Pre-clinical in vitro data describing the activity of a variety of PolyMedix's novel small molecule defensin mimetic antibiotic compounds against Mycobacterium tuberculosis, the bacteria which causes tuberculosis, were presented.

PolyMedix's lead antibiotic product candidate, PMX-30063, with an initial planned indication to broadly treat Staph infections, is currently undergoing Phase I clinical testing.

About PolyMedix, Inc.

PolyMedix is a publicly traded biotechnology company focused on the development of novel drugs and biomaterials for the treatment of infectious diseases and acute cardiovascular disorders. PolyMedix's compounds are based on biomimetics: non-peptide small molecule drugs and polymers that mimic the activity of proteins. The Company's antibiotic compounds, including PMX-30063 - small molecule mimetics of human host-defense proteins - have a completely different mechanism of action from current antibiotic drugs, a mechanism which is intended to make bacterial resistance unlikely to develop. These compounds are being developed as rapidly acting antibiotics for serious systemic and local infections. The Company plans to continue the development of polymeric formulations as antimicrobial biomaterials, which can be used as additives to paints, plastics, and textiles to create self-sterilizing products and surfaces. The Company's heptagonist compounds, including PMX-60056, reverse the activity of both heparin and Low Molecular Weight Heparins, with the goal of developing an antagonist drug that is safer and easier to use than currently approved therapy. PMX-30063 antibiotic and PMX-60056 heptagonist are currently undergoing clinical testing. For more information, please visit PolyMedix on its website at http://www.polymedix.com.

PolyMedix, Inc.

• Additional
• References
• Citations